Cost-Effectiveness Metrics Payers Seek for Digital Therapeutics

Opinion
Video

Diana Brixner, PhD, FAMCP, examines the payer perspective on including Prescription Digital Therapeutics in formularies, utilizing real-world evidence as a key metric to assess the impact, cost-effectiveness, and patient benefit of these innovative digital treatments.

Recent Videos
1 Kol is featured in this series
1 KOL is featured in this series.
1 KOL is featured in this series.
1 Kol is featured in this series
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.